Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit

Johnson & Johnson (NYSE:JNJ), connected Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% twelvemonth implicit year, beating the consensus of $2.60.

The pharmaceutical elephantine reported income of $21.89 billion, up 2.4% twelvemonth implicit twelvemonth and beating the consensus of $21.58 billion.

Operational maturation was 4.2%, and adjusted operational maturation was 3.3%. Innovative Medicine income accrued 2.3% oregon 4.2 operationally to $13.90 billion.

Also Read: Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study

Growth was driven by Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Erleada (apalutamide), Rybrevant/Lazcluze successful oncology, Tremfya (guselkumab) and Simponi/Simponi Aria successful immunology, Spravato (esketamine) Neuroscience, and Xarelto successful cardiovascular. Growth was partially offset by an approximate (810) ground points interaction from Stelara (ustekinumab) successful immunology.

Cancer income accrued to $5.68 billion, up 17.9% (+20.4 operational).

Immunology income fell to $3.71 billion, down 12.7% (down 10.9% operational).

Stelara sales fell 33.7% to $1.63 billion. Darzalex income roseate 20.3% to $3.24 billion. The company’s crab compartment therapy, Carvykti, generated income of $369 million.

MedTech income accrued 2.5% to 8.02 billion, driven chiefly by Abiomed successful cardiovascular and coiled closure products successful wide surgery. Growth was partially offset by Spine, Sports & Other successful Orthopaedics.

Dividend: Johnson & Johnson besides announced an summation successful its quarterly dividend from $1.24 to $1.30 per share. The 4.8% accrued dividend is payable connected June 10, with a grounds day of May 27.

Guidance: Johnson & Johnson expects 2025 income of $91 billion-$91.8 cardinal versus anterior guidance of $90.9 billion–$91.7 cardinal and statement of $90.62 billion

The Medtech elephantine expects 2025 adjusted operational EPS of $10.50-$10.70, compared to anterior guidance of $10.75–$10.95. It maintained the adjusted EPS outlook of $10.50-$10.70 versus the statement of $10.50.

Adjusted operational EPS excluded the interaction of translational currency, which means JNJ anticipates a deed to the bottomline from the interaction currency.

The institution anticipates second-half operational income maturation higher than the archetypal fractional of 2025.

Johnson & Johnson said the summation successful full-year 2025 operational sales guidance reflects the summation of CAPLYTA pursuing the completion of the Intra-Cellular Therapies acquisition.

Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated overseas exchange, the institution maintains a full-year 2025 adjusted reported EPS outlook of 6.2% maturation astatine the mid-point.